Top-Rated StocksTop-RatedNASDAQ:MAZE Maze Therapeutics (MAZE) Stock Price, News & Analysis $31.01 -0.94 (-2.94%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$30.96 -0.05 (-0.16%) As of 10/23/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Maze Therapeutics Stock (NASDAQ:MAZE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Maze Therapeutics alerts:Sign Up Key Stats Today's Range$30.54▼$31.8650-Day Range$22.39▼$32.5852-Week Range$21.95▼$53.65Volume512,936 shsAverage Volume874,710 shsMarket Capitalization$1.72 billionP/E RatioN/ADividend YieldN/APrice Target$64.45Consensus RatingBuy Company Overview Maze Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for patients with genetically driven diseases. The company uses human genetics and its proprietary Maze Compass platform to identify disease mechanisms, discover drug targets and design therapies intended to address the underlying biology of serious conditions. Maze’s pipeline has included small-molecule programs for rare diseases, including MZE001, an investigational glycogen synthase 1 inhibitor being developed for Pompe disease. The company has also pursued additional programs directed at genetically validated targets in areas such as kidney and metabolic diseases. Its product candidates remain investigational and require clinical testing and regulatory review before they can be marketed. Founded in 2018 and based in South San Francisco, California, Maze Therapeutics conducts its research and development activities primarily in the United States. The company is led by President and Chief Executive Officer Jason Coloma, who has experience in biotechnology company building, drug development and venture investment.AI Generated. May Contain Errors. Read More Maze Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreMAZE MarketRank™: 3.082494969815 of 5 starsMaze Therapeutics scored higher than 62% of companies evaluated by MarketBeat, and ranked 323rd out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingMaze Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.07, and is based on 3 strong buy ratings, 10 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialMaze Therapeutics has a consensus price target of $64.45, representing about 107.9% upside from its current price of $31.01.Amount of Analyst CoverageMaze Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Maze Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Maze Therapeutics are expected to decrease in the coming year, from ($2.70) to ($3.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Maze Therapeutics is -12.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Maze Therapeutics is -12.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMaze Therapeutics has a P/B Ratio of 4.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.48% of the float of Maze Therapeutics has been sold short.Short Interest Ratio / Days to CoverMaze Therapeutics has a short interest ratio ("days to cover") of 6.07.Change versus previous monthShort interest in Maze Therapeutics has recently increased by 15.62%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMaze Therapeutics does not currently pay a dividend.Dividend GrowthMaze Therapeutics does not have a long track record of dividend growth. News and Social Media4.1 / 5News Sentiment0.62 News SentimentMaze Therapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Maze Therapeutics this week, compared to 4 articles on an average week.Search Interest3 people have searched for MAZE on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows3 people have added Maze Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Maze Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,152,084.00 in company stock.Percentage Held by Insiders5.30% of the stock of Maze Therapeutics is held by insiders.Percentage Held by InstitutionsMaze Therapeutics has minimal institutional ownership at this time.Read more about Maze Therapeutics' insider trading history. Receive MAZE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Maze Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MAZE Stock News HeadlinesMaze Therapeutics (NASDAQ:MAZE) Stock Rated "Buy" in New Coverage at Canaccord Genuity GroupOctober 22 at 2:26 AM | americanbankingnews.comMaze Therapeutics, Inc. (MAZE) Latest Stock News & Headlines - Yahoo FinanceOctober 21, 2026 | finance.yahoo.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.October 25 at 1:00 AM | Porter & Company (Ad)Maze Therapeutics adjusts equity via warrant exchangeOctober 16, 2026 | tipranks.comMaze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026October 6, 2026 | globenewswire.com3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight (MAZE)Small-cap stocks Ascentage Pharma, Maze Therapeutics, and Pagaya Technologies show improving fundamentals, strong cash positions, and bullish analyst ratings amid shifting investor interest.October 5, 2026 | marketbeat.comMaze Therapeutics (NASDAQ:MAZE) CMO Harold Bernstein Sells 16,141 Shares of StockOctober 3, 2026 | insidertrades.comMaze Therapeutics (NASDAQ:MAZE) Insider Atul Dandekar Sells 7,500 Shares of Company StockOctober 2, 2026 | insidertrades.comSee More Headlines MAZE Stock Analysis - Frequently Asked Questions How have MAZE shares performed this year? Maze Therapeutics' stock was trading at $41.43 at the start of the year. Since then, MAZE shares have decreased by 25.2% and is now trading at $31.01. How were Maze Therapeutics' earnings last quarter? Maze Therapeutics, Inc. (NASDAQ:MAZE) posted its earnings results on Tuesday, August, 11th. The company reported ($0.76) EPS for the quarter, hitting the consensus estimate of ($0.76). When did Maze Therapeutics IPO? Maze Therapeutics (MAZE) raised $140 million in an IPO on Friday, January 31st 2025. The company issued 8,750,000 shares at a price of $15.00-$17.00 per share. Who are Maze Therapeutics' major shareholders? Top institutional investors of Maze Therapeutics include Sterling Capital Management LLC. Insiders that own company stock include Atul Dandekar, Harold Bernstein, Jason V Coloma, Amy Bachrodt, Phillips Courtney and Richard H Scheller. View institutional ownership trends. How do I buy shares of Maze Therapeutics? Shares of MAZE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Maze Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Maze Therapeutics investors own include ImmunityBio (IBRX), NVIDIA (NVDA), Micron Technology (MU), Uranium Energy (UEC), Nebius Group (NBIS), Advanced Micro Devices (AMD) and Broadcom (AVGO). Company Calendar Last Earnings8/11/2026Today10/25/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 MAZE's financial health is in the Red zone, according to TradeSmith. MAZE has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:MAZE Previous SymbolNASDAQ:MAZE CIK1842295 Webmazetx.com Phone(650) 850-5070FaxN/AEmployees141Year Founded2018Price Target and Rating Average Price Target for Maze Therapeutics$64.45 High Price Target$110.00 Low Price Target$46.00 Potential Upside/Downside+107.9%Consensus RatingBuy Rating Score (0-4)3.07 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($2.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$131.12 million Net MarginsN/A Pretax Margin-667.95% Return on Equity-34.94% Return on Assets-30.18% Debt Debt-to-Equity Ratio0.09 Current Ratio18.31 Quick Ratio18.31 Sales & Book Value Annual Sales$167.50 million Price / Sales10.28 Cash FlowN/A Price / Cash FlowN/A Book Value$7.38 per share Price / Book4.20Miscellaneous Outstanding Shares55,550,000Free Float52,605,000Market Cap$1.72 billion OptionableOptionable Beta2.16 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:MAZE) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersWhy tech stocks are deadAI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the b...Porter & Company | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredThe $100 Stock Behind Elon's Next MoveA small, publicly traded supplier trading under $100 a share has reportedly worked alongside Elon Musk for mor...Paradigm Press | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maze Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maze Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
